What is Cervical Cancer?What is the HPV vaccine? HPV VaccinationHPV Vaccine Implementation Status in Japan12entrance to the uterus (cervix).woman in Japan are diagnosed with this disease every year. In Japan, about 11,000 women are diagnosed with cervical cancer each year, and of these, approximately 2,900 die. The number of patients begins to increase, especially among those in their 20s, and many women lose their uterus in their 30s. Cervical cancer is often thought of as a disease of The HPV vaccine is a vaccine that prevents infection with the human papillomavirus (HPV), the cause of cervical cancer.vaccination recommendations, but recommendations resumed in April 2022, and catch-up vaccination has begun.completed the third dose of the HPV vaccine between April 1, 2022, when active vaccination recommendations resumed, and September 30, 2024-a period of about 2.5 years In Japan, vaccination against HPV infection (HPV vaccine), which causes cervical cancer, is offered to girls from the sixth grade of elementary school to the equivalent of the first grade of high school. Those who are eligible can receive the vaccination at public expense.There are currently three types of HPV vaccines available in Japan at public expense, depending on the type of HPV that can be prevented: bivalent vaccine (Cervarix®), quadrivalent Regarding the HPV Vaccination Status in Japan. I found a survey on the number of girls who were vaccinated with the conventional routine vaccination between the first day of the fiscal year in which they turned 12 years old and the last day of the fiscal year in which they turned 16 years old. annual coverage rate for individuals who received the first dose of the HPV vaccine was 42.1% in 2022 and increased to 62.1% in 2023. The coverage rate for those who completed the second dose was 38.6% in 2022 and 40.1% in 2023. For those who completed all three doses, the rate was 29.0% in 2022 but decreased to 24.9% in 2023. These figures indicate an overall increase in initial and second-dose vaccination rates between 2022 and 2023, although older people, but in fact, it is more common among younger woman in their 20s and 30s. Therefore, early prevention and regular checkups are very important. The number of people who will develop cervical cancer in their lifetime is 132 per 10,000 (converted as a class of approximately 35 girls per class), or one out of every two classes. The number of deaths from cervical cancer is 34 per 10,000, or about 1 in 10 classes.vaccine (Gardasil®), and 9-valent vaccine (Sylgard®9). A total of two or three doses of the same vaccine are administered at regular intervals. The timing and number of vaccinations vary depending on the vaccine and the age of the child. The figure below is an example of intervals for Silgard 9.the completion rate for the third dose declined slightly. Comparison with Other Countries As of January 2024, the HPV vaccine has been introduced into national immunization programs in 137 countries, or more than 70% of the 194 member countries of the World Health Organization (WHO). 59 of the 137 countries offer the vaccine to men as well as women. Based on WHO data, HPV vaccine completion rates in G7 countries other than Japan vary from country to country, but more than half exceed 50%. In 2019, the WHO set a goal to eradicate cervical cancer, with a target of 90% HPV vaccination coverage among girls up to age 15 by 2030. Cervical cancer is a type of cancer that develops at the It is especially common among young women, and many The HPV vaccine was temporarily withheld from active It is known that approximately 940,000 people have According to surveys conducted up to 2024, the national
元のページ ../index.html#13